PREFERRED STOCK PURCHASE AGREEMENT BETWEEN LAB123, INC. AND BARRON PARTNERS LP DATED SEPTEMBER 6, 2006
Exhibit
10.3
BETWEEN
AND
▇▇▇▇▇▇
PARTNERS LP
DATED
SEPTEMBER
6, 2006
This
PREFERRED STOCK PURCHASE AGREEMENT (the "Agreement")
is
made and entered into as of the 6th day of September, 2006 between LAB123,
Inc., a
corporation organized and existing under the laws of the State of Delaware
(“Lab123”
or the “Company”)
and
▇▇▇▇▇▇
PARTNERS LP, a
Delaware limited partnership (“Investor”).
PRELIMINARY
STATEMENT:
WHEREAS,
the
Investor wishes to purchase from the Company, upon the terms and subject to
the
conditions of this Agreement, Three Million Seven Hundred Seventy-Four Thousand
(3,774,000) shares of preferred stock of the Company, with such preferred stock
being as described in the Certificate of Designations, Rights and Preferences
(the “Certificate
of Designations”)
in
substantially the form attached hereto as Exhibit
A
(the
“Preferred
Stock”)
for the
Purchase Price set forth in Section 1.3.13 hereof. Subject to the limitations
set forth herein and in the Certificate of Designations, the Preferred Stock
shall be initially convertible into shares of common stock of the Company at
any
time at a conversion price of Fifty-Three Cents ($0.53) per share (the
“Conversion
Value”).
In
addition, the Company will issue to the Investor two five year Common Stock
Purchase Warrants, substantially in the form of Exhibits
B and C
(the
“Warrants”),
the
first of which shall be for the purchase of an aggregate of 1,887,000 shares
at
an initial exercise price of $.80 per share and the second of which shall be
for
the purchase of an aggregate of 1,887,000 shares at an initial exercise price
of
$1.10 per share; and
WHEREAS,
the
parties intend to memorialize the purchase and sale of such Preferred Stock
and
the Warrants.
NOW,
THEREFORE,
in
consideration of the mutual covenants and premises contained herein, and for
other good and valuable consideration, the receipt and adequacy of which are
hereby conclusively acknowledged, the parties hereto, intending to be legally
bound, agree as follows:
ARTICLE
I
INCORPORATION
BY REFERENCE, SUPERSEDER AND DEFINITIONS
1.1 Incorporation
by Reference.
The
foregoing recitals and the Exhibits and Schedules attached hereto and referred
to herein, are hereby acknowledged to be true and accurate, and are incorporated
herein by this reference.
1.2 Supersede.
This
Agreement, to the extent that it is inconsistent with any other instrument
or
understanding among the parties governing the affairs of the Company, shall
supersede such instrument or understanding to the fullest extent permitted
by
law. A copy of this Agreement shall be filed at the Company’s principal
office.
1.3 Certain
Definitions.
For
purposes of this Agreement, the following capitalized terms shall have the
following meanings (all capitalized terms used in this Agreement that are not
defined in this Article 1 shall have the meanings set forth elsewhere in this
Agreement):
1.3.1 “1933
Act”
means
the Securities Act of 1933, as amended.
1.3.2 “1934
Act”
means
the Securities Exchange Act of 1934, as amended.
1.3.3 “Affiliate”
means
a
Person or Persons directly or indirectly, through one or more intermediaries,
controlling, controlled by or under common control with the Person(s) in
question. The term “control,” as used in the immediately preceding sentence,
means, with respect to a Person that is a corporation, the right to the
exercise, directly or indirectly, of more than 50 percent of the voting rights
attributable to the shares of such controlled corporation and, with respect
to a
Person that is not a corporation, the possession, directly or indirectly, of
the
power to direct or cause the direction of the management or policies of such
controlled Person.
1.3.4 “Articles”
means
the Certificate of Incorporation of the Company, as the same may be amended
from
time to time.
1.3.5 “Closing”
shall
mean the Closing of the transactions contemplated by this Agreement on the
Closing Date.
1.3.6 “Closing
Date”
means
the date on which the payment of the Purchase Price (as defined herein) by
the
Investor to the Company is completed pursuant to this Agreement to purchase
the
Preferred Stock and Warrants, which shall occur on or before September 6,
2006.
1.3.7 “Common
Stock”
means
shares of common stock of the Company, par value $0.001 per share.
1.3.8 "Escrow
Agreement"
shall
mean the Escrow Agreement among the Company, the Investor and Sichenzia ▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ LLP, as Escrow Agent, attached hereto as Exhibit
E.
1.3.9 "Exempt
Issuance"
means
the issuance of (a) shares of Common Stock or options to employees, officers,
or
directors of the Company pursuant to any stock or option plan duly adopted
by a
majority of the non-employee members of the Board of Directors of the Company
or
a majority of the members of a committee of non-employee directors established
for such purpose, (b) securities upon the exercise of or conversion of any
securities issued hereunder, and (c) securities issued pursuant to acquisitions
or strategic transactions, provided any such issuance shall only be to a Person
which is, itself or through its subsidiaries, an operating company in a business
synergistic with the business of the Company and in which the Company receives
benefits in addition to the investment of funds, but shall not include a
transaction in which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is investing in
securities.
1.3.10 "Material
Adverse Effect"
shall
mean any adverse effect on the business, operations, properties or financial
condition of the Company that is material and adverse to the Company and its
subsidiaries and affiliates, taken as a whole and/or any condition,
circumstance, or situation that would prohibit or otherwise materially interfere
with the ability of the Company to perform any of its material obligations
under
this Agreement or the Registration Rights Agreement or to perform its
obligations under any other material agreement.
1.3.11 “Delaware
Act”
means
the Delaware General Corporation Law, as amended.
1.3.12 “Person”
means
an individual, partnership, firm, limited liability company, trust, joint
venture, association, corporation, or any other legal entity.
1.3.13 “Purchase
Price”
means
the Two Million ($2,000,000.00) dollars paid by the Investor to the Company
for
the Preferred Stock and the Warrants.
1.3.14 “Registration
Rights Agreement"
shall
mean the registration rights agreement between the Investor and the Company
attached hereto as Exhibit
D.
1.3.15 "Registration
Statement"
shall
mean the registration statement under the 1933 Act to be filed with the SEC
for
the registration of the Shares pursuant to the Registration Rights Agreement
attached hereto as Exhibit
D.
1.3.16 “SEC”
means
the Securities and Exchange Commission.
1.3.17 "SEC
Documents"
shall
mean the Company's latest Form 10-K or 10-KSB as of the time in question, all
Forms 10-Q or 10-QSB and 8-K filed thereafter, and the Proxy Statement for
its
latest fiscal year as of the time in question until such time as the Company
no
longer has an obligation to maintain the effectiveness of a Registration
Statement as set forth in the Registration Rights Agreement.
1.3.18
"Shares"
shall
mean, collectively, the shares of Common Stock of the Company issued upon
conversion of the Preferred Stock subscribed for hereunder and those shares
of
Common Stock issuable to the Investor upon exercise of the
Warrants.
1.3.19
“Subsequent
Financing”
shall
mean any offer and sale of shares of Preferred Stock or debt that is initially
convertible into shares of Common Stock or otherwise senior or superior to
the
Preferred Stock.
1.3.20
“Transaction
Documents”
shall
mean this Agreement, all Schedules and Exhibits attached hereto and all other
documents and instruments to be executed and delivered by the parties in order
to consummate the transactions contemplated hereby, including, but not limited
to, the documents listed in Sections 3.2 and 3.3 hereof.
1.3.21 “Warrants”
shall
mean the Common Stock Purchase Warrants in the form attached hereto as
Exhibits
B and C.
ARTICLE
II
SALE
AND PURCHASE OF PREFERRED STOCK AND WARRANTS
2.1Sale
of Preferred Stock and Issuance of Warrants.
(a) Upon
the
terms and subject to the conditions set forth herein, and in accordance with
applicable law, the Company agrees to sell to the Investor, and the Investor
agrees to purchase from the Company, on the Closing Date 3,774,000 shares of
Preferred Stock and the Warrants for the aggregate purchase price (the
“Purchase
Price”)
of Two
Million Dollars ($2,000,000.00). The Purchase Price shall be paid by the
Investor to the Company on the Closing Date by a wire transfer or check of
the
Purchase Price into escrow to be held by the escrow agent pursuant to the terms
of the Escrow Agreement. The Company shall cause the Preferred Stock and the
Warrants to be issued to the Investor at the Closing upon the release of the
Purchase Price to the Company. by the escrow agent pursuant to the terms of
the
Escrow Agreement. The Company shall register the shares of Common Stock into
which the Preferred Stock is convertible pursuant to the terms and conditions
of
a Registration Rights Agreement attached hereto as Exhibit
D.
(b) Each
share of Preferred Stock shall initially be convertible by the Investor into
one
(1) share of Common Stock; provided, however, that the Investor shall not be
entitled to convert the Preferred Stock into shares of Common Stock that would
result in beneficial ownership by the Investor and its affiliates of more than
4.9% of the then outstanding number of shares of Common Stock on such date.
For
the purposes of the immediately preceding sentence, beneficial ownership shall
be determined in accordance with Section 13(d) of the Securities Exchange Act
of
1934, as amended, and Regulation 13d-3 thereunder.
(c) Upon
execution and delivery of this Agreement and the Company’s receipt of the
Purchase Price from the Escrow Agent pursuant to the terms of the Escrow
Agreement, the Company shall issue to the Investor the Warrants to purchase
an
aggregate of Three Million Seven Hundred Seventy-Four Thousand shares of Common
Stock at exercise prices as stated in the Warrants, all pursuant to the terms
and conditions of the form of Warrants attached hereto as Exhibits
B and C;
provided, however, that the Investor shall not be entitled to exercise the
Warrants and receive shares of Common Stock that would result in beneficial
ownership by the Investor and its affiliates of more than 4.9% of the then
outstanding number of shares of Common Stock on such date. For the purposes
of
the immediately preceding sentence, beneficial ownership shall be determined
in
accordance with Section 13(d) of the Securities Exchange Act of 1934, as
amended, and Regulation 13d-3 thereunder.
2.2 Purchase
Price.
The
Purchase Price shall be delivered by the Investor in the form of a check or
wire
transfer made payable to the Company in United States Dollars from the Investor
to the escrow agent pursuant to the Escrow Agreement on the Closing
Date.
ARTICLE
III
CLOSING
DATE AND DELIVERIES AT CLOSING
3.1 Closing
Date. The
closing of the transactions contemplated by this Agreement (the “Closing”),
unless expressly determined herein, shall be held at the offices of the Company,
at 5:00 P.M. local time, on the Closing Date or on such other date and at such
other place as may be mutually agreed by the parties, including closing by
facsimile with originals to follow. The Closing shall be deemed to occur upon
the delivery of the items sets forth in Section 3.2 to the respective
parties.
3.2 Deliveries
by the Company.
In
addition to and without limiting any other provision of this Agreement, the
Company agrees to deliver, or cause to be delivered, to the escrow agent under
the Escrow Agreement, the following:
| (a) |
At
or prior to Closing, an executed Agreement with all exhibits and
schedules
attached hereto;
|
| (b) |
At
or prior to Closing, executed Warrants in the name of the Investor
in the
forms attached hereto as Exhibits
B and C;
|
| (c) |
The
executed Registration Rights
Agreement;
|
| (d) |
Certifications
in form and substance acceptable to the Company and the Investor
from any
and all brokers or agents involved in the transactions contemplated
hereby
as to the amount of commission or compensation payable to such broker
or
agent as a result of the consummation of the transactions contemplated
hereby and from the Company or Investor, as appropriate, to the effect
that reasonable reserves for any other commissions or compensation
that
may be claimed by any broker or agent have been set
aside;
|
| (e) |
Management
letter from the auditors of the Company and MD&A;
|
| (f) |
Evidence
of approval of the Board of Directors and Shareholders of the Company
of
the Transaction Documents and the transactions contemplated
hereby;
|
| (g) |
Certificate
of the President and the Secretary of the Company that the Certificate
of
Designation has been adopted and
filed;
|
| (h) |
Certificates
of Existence or Authority to Transact Business of the Company issued
by
the Secretary of State for
Delaware;
|
| (i) |
An
opinion from the Company’s counsel concerning the Transaction Documents
and the transactions contemplated hereby in form and substance reasonably
acceptable to Investor
|
| (j) |
Stock
Certificate in the name of Investor evidencing the Preferred
Stock;
|
| (k) |
The
executed Escrow Agreement (an additional copy of which shall be delivered
to the Investor at the Closing);
and
|
| (l) |
Copies
of all executive employment agreements, all past and present financing
documentation or other documentation where stock could potentially
be
issued or issued as payment, all past and present litigation documents
and
historical financials.
|
| (m) |
Such
other documents or certificates as shall be reasonably requested
by
Investor or its counsel.
|
3.3 Deliveries
by Investor.
In
addition to and without limiting any other provision of this Agreement, the
Investor agrees to deliver, or cause to be delivered, to the escrow agent under
the Escrow Agreement, the following:
| (a) |
A
deposit in the amount of the Purchase
Price;
|
| (b) |
The
executed Agreement with all Exhibits and Schedules attached
hereto;
|
| (c) |
The
executed Registration Rights Agreement;
|
| (d) |
The
executed Escrow Agreement (an additional copy of which shall be delivered
to the Company at the Closing); and
|
| (e) |
Such
other documents or certificates as shall be reasonably requested
by the
Company or its counsel.
|
In
the
event any document provided to the other party in Paragraphs 3.2 and 3.3 herein
are provided by facsimile, the party shall forward an original document to
the
other party within five (5) business days.
3.4 Further
Assurances.
The
Company and the Investor shall, upon request, on or after the Closing Date,
cooperate with each other (specifically, the Company shall cooperate with the
Investor, and the Investor shall cooperate with the Company) by furnishing
any
additional information, executing and delivering any additional documents and/or
other instruments and doing any and all such things as may be reasonably
required by the parties or their counsel to consummate or otherwise implement
the transactions contemplated by this Agreement.
3.5 Waiver.
The
Investor may waive any of the requirements of Section 3.2 of this Agreement,
and
the Company at its discretion may waive any of the provisions of Section 3.3
of
this Agreement. The Investor may also waive any of the requirements of the
Company under the Escrow Agreement.
ARTICLE
IV
REPRESENTATIONS
AND WARRANTIES OF
THE
COMPANY
The
Company represents and warrants to the Investor as of the date hereof and as
of
Closing (which warranties and representations shall survive the Closing
regardless of what examinations, inspections, audits and other investigations
the Investor has heretofore made or may hereinafter make with respect to such
warranties and representations) as follows:
4.1 Organization
and Qualification.
The
Company is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware, and has the requisite corporate power
and authority to own, lease and operate its properties and to carry on its
business as it is now being conducted and is duly qualified to do business
in
any other jurisdiction by virtue of the nature of the businesses conducted
by it
or the ownership or leasing of its properties, except where the failure to
be so
qualified will not, when taken together with all other such failures, have
a
Material Adverse Effect on the business, operations, properties, assets,
financial condition or results of operation of the Company and its subsidiaries
taken as a whole.
4.2 Articles
of Incorporation and By-Laws.
The
complete and correct copies of the Company’s Articles and By-Laws, as amended or
restated to date, are complete and correct copies of such documents as in effect
on the date hereof and will also be such as of the Closing Date.
4.3 Capitalization.
4.3.1 As
of the
date of this Agreement, the authorized capital stock of the Company consists
of
15,000,000 shares of Common Stock,$.001 par value per share (“Common Stock”) and
6,000,000 shares of Preferred Stock, $.001 par value per share (“Preferred
Stock”), of which no shares of Common Stock and no shares of Preferred Stock are
issued and outstanding on the date hereof. As of Closing, following the issuance
by the Company of the Preferred Stock to the Investor, the authorized capital
stock of the Company will consist of 15,000,000 shares of Common Stock and
6
million shares of Preferred Stock of which approximately 7,825,000 shares of
Common Stock and 3,774,000 shares of Preferred Stock shall be issued and
outstanding. As of the date hereof there no outstanding options, warrants or
other securities exercisable or exchangeable for or convertible into, Common
Stock. As of the Closing, except for the Warrants to be issued to the Investor,
there will be no outstanding options, warrants or other securities exercisable
or exchangeable for or convertible into, Common Stock All outstanding shares
of
capital stock have been duly authorized and are validly issued, and are fully
paid and nonassessable and free of preemptive rights. All shares of capital
stock described above to be issued have been duly authorized and when issued,
will be validly issued, fully paid and nonassessable and free of preemptive
rights. Schedule 4.3 contains all shares and derivatives currently and
potentially outstanding. The Company hereby represents that any and all shares
and current potentially dilutive events have been included in Schedule 4.3.,
including employment agreements, acquisition, consulting agreements, debts,
payments, financing or business relationships that could be paid in equity,
derivatives or resulting in additional equity issuances that could potentially
occur.
4.3.2
Except pursuant to this Agreement and as set forth in Schedule 4.3 hereto,
as of
the date hereof and as of the Closing Date, there are not now outstanding
options, warrants, rights to subscribe for, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into
or
exchangeable for, shares of any class of capital stock of the Company, or
agreements, understandings or arrangements to which the Company is a party,
or
by which the Company is or may be bound, to issue additional shares of its
capital stock or options, warrants, scrip or rights to subscribe for, calls
or
commitment of any character whatsoever relating to, or securities or rights
convertible into or exchangeable for, any shares of any class of its capital
stock. The Company agrees to inform the Investors in writing of any additional
warrants granted prior to the Closing Date.
4.3.3
The
Company on the Closing Date (i) will have full right, power, and authority
to
sell, assign, transfer, and deliver, by reason of record and beneficial
ownership, to the Investor, the Preferred Stock hereunder, free and clear of
all
liens, charges, claims, options, pledges, restrictions, and encumbrances
whatsoever; and (ii) upon conversion of the Preferred Stock or exercise of
the
Warrants, the Investor will acquire good and marketable title to the Shares
,
free and clear of all liens, charges, claims, options, pledges, restrictions,
and encumbrances whatsoever, except as otherwise provided in this Agreement
as
to the limitation on the voting rights of such Shares in certain
circumstances.
4.4 Authority.
The
Company has all requisite corporate power and authority to execute and deliver
this Agreement, the Preferred Stock, and the Warrants, to perform its
obligations hereunder and thereunder and to consummate the transactions
contemplated hereby and thereby. The execution and delivery of this Agreement
by
the Company and the consummation of the transactions contemplated hereby have
been duly authorized by all necessary corporate action and no other corporate
proceedings on the part of the Company is necessary to authorize this Agreement
or to consummate the transactions contemplated hereby, except as disclosed
in
this Agreement. This Agreement has been duly executed and delivered by the
Company and constitutes the legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms.
4.5 No
Conflict; Required Filings and Consents.
The
execution and delivery of this Agreement by the Company does not, and the
performance by the Company of their respective obligations hereunder will not:
(i) conflict with or violate the Articles or By-Laws of the Company; (ii)
conflict with, breach or violate any federal, state, foreign or local law,
statute, ordinance, rule, regulation, order, judgment or decree (collectively,
"Laws")
in
effect as of the date of this Agreement and applicable to the Company; or (iii)
result in any breach of, constitute a default (or an event that with notice
or
lapse of time or both would become a default) under, give to any other entity
any right of termination, amendment, acceleration or cancellation of, require
payment under, or result in the creation of a lien or encumbrance on any of
the
properties or assets of the Company pursuant to, any note, bond, mortgage,
indenture, contract, agreement, lease, license, permit, franchise or other
instrument or obligation to which the Company is a party or by the Company
or
any of its properties or assets is bound. Excluding from the foregoing are
such
violations, conflicts, breaches, defaults, terminations, accelerations,
creations of liens, or incumbency that would not, in the aggregate, have a
Material Adverse Effect.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE8
OF
34
4.6 Audited
Report and Financial Statements.
The
Company will provide to the Investor the audited financial statements of the
Company as of August 31, 2006 and for the period from inception of the Company
to August 31, 2006 (collectively, the “Financial
Statements”)
prior
to the release of funds by the escrow agent pursuant to the Escrow Agreement.
The balance sheet contained in such Financial Statements (including the related
notes and schedules thereto) fairly presented the financial position of the
Company, as of its date, and the statement of income and changes in
stockholders’ equity and cash flows or equivalent statements in such Financial
Statements (including any related notes and schedules thereto) fairly presents,
changes in stockholders’ equity and changes in cash flows, as the case may be,
of the Company, for the periods to which they relate, in each case in accordance
with United States generally accepted accounting principles (“U.S.
GAAP”)
consistently applied during the periods involved, except in each case as may
be
noted therein, subject to normal year-end audit adjustments. The books and
records of the Company have been, and are being, maintained in all material
respects in accordance with U.S. GAAP and any other applicable legal and
accounting requirements and reflect only actual transaction.
4.7 Compliance
with Applicable Laws.
The
Company is not in violation of, or, to the knowledge of the Company, under
investigation with respect to, or has been given notice or has been charged
with
the violation of, any Law of a governmental agency, except for violations which
individually or in the aggregate do not have a Material Adverse Effect.
4.8 Brokers.
Except
as set forth on Schedule 4.8, no broker, finder or investment banker is entitled
to any brokerage, finder's or other fee or commission in connection with the
transactions contemplated by this Agreement based upon arrangements made by
or
on behalf of the Company.
4.9 Litigation.
To the
knowledge of the Company, no litigation, claim, or other proceeding before
any
court or governmental agency is pending or to the knowledge of the Company,
threatened against the Company, the prosecution or outcome of which may have
a
Material Adverse Effect.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE9
OF
34
4.10 Exemption
from Registration.
Subject
to the accuracy of the Investor’s representations in Article V, except as
required pursuant to the Registration Rights Agreement, the sale of the Common
Stock and Warrants by the Company to the Investor will not require registration
under the 1933 Act, but may require registration or an exemption from
registration under New York state securities law if applicable to the Investor.
When validly converted in accordance with the terms of the Preferred Stock,
and
upon exercise of the Warrants in accordance with their terms, the Shares
underlying the Preferred Stock and the Warrants will be duly and validly issued,
fully paid, and non-assessable. The Company is issuing the Preferred Stock
and
the Warrants in accordance with and in reliance upon the exemption from
securities registration afforded, inter alia, by Rule 506 under Regulation
D as
promulgated by the SEC under the 1933 Act, and/or Section 4(2) of the 1933
Act;
provided, however, that certain filings and registrations may be required under
state securities “blue sky” laws depending upon the residency of the
Investor.
4.11 No
General Solicitation or Advertising in Regard to this
Transaction.
Neither
the Company nor any of its Affiliates nor, to the knowledge of the Company,
any
Person acting on its or their behalf (i) has conducted or will conduct any
general solicitation (as that term is used in Rule 502(c) of Regulation D as
promulgated by the SEC under the ▇▇▇▇ ▇▇▇) or general advertising with respect
to the sale of the Preferred Stock or Warrants, or (ii) made any offers or
sales
of any security or solicited any offers to buy any security under any
circumstances that would require registration of the Preferred Stock or
Warrants, under the 1933 Act, except as required herein.
4.12 No
Material Adverse Effect.
Except
as set forth in Schedule 4.12 attached hereto, since June 30, 2006, no event
or
circumstance resulting in a Material Adverse Effect has occurred or exists
with
respect to the Company. No material supplier or customer has given notice,
oral
or written, that it intends to cease or reduce the volume of its business with
the Company from historical levels. Since June 30, 2006, no event or
circumstance has occurred or exists with respect to the Company or its
businesses, properties, prospects, operations or financial condition, that,
under any applicable law, rule or regulation, requires public disclosure or
announcement prior to the date hereof by the Company, but which has not been
so
publicly announced or disclosed in writing to the Investor.
4.13 Material
Non-Public Information.
The
Company has not disclosed to the Investor any material non-public information
that (i) if disclosed, would reasonably be expected to have a material effect
on
the price of the Common Stock or (ii) according to applicable law, rule or
regulation, should have been disclosed publicly by the Company prior to the
date
hereof, but which has not been so disclosed.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE10
OF
34
4.14 Internal
Controls And Procedures.
The
Company maintains books and records and internal accounting controls which
provide reasonable assurance that (i) all transactions to which the Company
or
any subsidiary is a party or by which its properties are bound are executed
with
management's authorization; (ii) the recorded accounting of the Company's
consolidated assets is compared with existing assets at regular intervals;
(iii)
access to the Company's consolidated assets is permitted only in accordance
with
management's authorization; and (iv) all transactions to which the Company
or
any subsidiary is a party or by which its properties are bound are recorded
as
necessary to permit preparation of the financial statements of the Company
in
accordance with U.S. generally accepted accounting principles.
4.15 Full
Disclosure.
No
representation or warranty made by the
Company in
this
Agreement and no certificate or document furnished or to be furnished to the
Investor pursuant to this Agreement contains or will contain any untrue
statement of a material fact, or omits or will omit to state a material fact
necessary to make the statements contained herein or therein not
misleading.
4.16 Independent
Board.
. Not
later than 30 days after the Closing, the Board of Directors of the Company
shall consist of five directors, three of whom shall be independent as such
term
is defined in Rule 4200(a)(15) promulgated by the National Association of
Securities Dealers, Inc. (the “NASD”).. Not later than 30 days after the Closing
Date of this Agreement, the Board of Directors shall have an Audit and
Compensation Committees of the Board of Directors of the Company comprised
of
independent directors.
ARTICLE
V
REPRESENTATIONS
AND WARRANTIES OF THE INVESTOR
The
Investor represents and warrants to the Company that:
5.1 Organization
and Standing of the Investor.
The
Investor is a limited partnership duly formed, validly existing and in good
standing under the laws of the State of Delaware. The state in which any offer
to purchase shares hereunder was made or accepted by such Investor is the state
shown as such Investor’s address. The Investor was not formed for the purpose of
investing solely in the Preferred Stock, the Warrants or the shares of Common
Stock which are the subject of this Agreement.
5.2 Authorization
and Power.
The
Investor has the requisite power and authority to enter into and perform this
Agreement and to purchase the securities being sold to it hereunder. The
execution, delivery and performance of this Agreement by the Investor and the
consummation by the Investor of the transactions contemplated hereby have been
duly authorized by all necessary partnership action where appropriate. This
Agreement and the Registration Rights Agreement have been duly executed and
delivered by the Investor and at the Closing shall constitute valid and binding
obligations of the Investor enforceable against the Investor in accordance
with
their terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation,
conservatorship, receivership or similar laws relating to, or affecting
generally the enforcement of, creditors' rights and remedies or by other
equitable principles of general application.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE11
OF
34
5.3 No
Conflicts.
The
execution, delivery and performance of this Agreement and the consummation
by
the Investor of the transactions contemplated hereby or relating hereto do
not
and will not (i) result in a violation of such Investor's limited partnership
agreement or certificate of limited partnership or (ii) conflict with, or
constitute a default (or an event which with notice or lapse of time or both
would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of any agreement, indenture or
instrument to which the Investor is a party, or result in a violation of any
law, rule, or regulation, or any order, judgment or decree of any court or
governmental agency applicable to the Investor or its properties (except for
such conflicts, defaults and violations as would not, individually or in the
aggregate, have a Material Adverse Effect on such Investor). The Investor is
not
required to obtain any consent, authorization or order of, or make any filing
or
registration with, any court or governmental agency in order for it to execute,
deliver or perform any of such Investor’s obligations under this Agreement or to
purchase the securities from the Company in accordance with the terms hereof,
provided that for purposes of the representation made in this sentence, the
Investor is assuming and relying upon the accuracy of the relevant
representations and agreements of the Company herein.
5.4 Financial
Risks.
The
Investor acknowledges that such Investor is able to bear the financial risks
associated with an investment in the securities being purchased by the Investor
from the Company and that it has been given full access to such records of
the
Company and the subsidiaries and to the officers of the Company and the
subsidiaries as it has deemed necessary or appropriate to conduct its due
diligence investigation. The Investor is capable of evaluating the risks and
merits of an investment in the securities being purchased by the Investor from
the Company by virtue of its experience (or the experience of its officers,
employees and partners) as an investor and its (or its officers’ employees’ or
partners’) knowledge, experience, and sophistication in financial and business
matters and the Investor is capable of bearing the entire loss of its investment
in the securities being purchased by the Investor from the Company.
5.5 Accredited
Investor.
The
Investor is (i) an “accredited investor” as that term is defined in Rule 501 of
Regulation D promulgated under the 1933 Act by reason of Rule 501(a)(3) and
(6),
(ii) experienced in making investments of the kind described in this Agreement
and the related documents, (iii) able, by reason of the business and financial
experience of its officers and professional advisors (who are not affiliated
with or compensated in any way by the Company or any of its affiliates or
selling agents), to protect its own interests in connection with the
transactions described in this Agreement, and the related documents, and (iv)
able to afford the entire loss of its investment in the securities being
purchased by the Investor from the Company.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE12
OF
34
5.6 Brokers.
Except
as set forth in Schedule 4.8, no broker, finder or investment banker is entitled
to any brokerage, finder's or other fee or commission in connection with the
transactions contemplated by this Agreement based upon arrangements made by
or
on behalf of the Investor.
5.7 Knowledge
of Company.
The
Investor and such Investor’s advisors, if any, have been, upon request,
furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the securities
being purchased by the Investor from the Company. The Investor and such
Investor’s advisors, if any, have been afforded the opportunity to ask questions
of the Company and have received complete and satisfactory answers to any such
inquiries.
5.8 Risk
Factors.
The
Investor understands that such Investor’s investment in the securities being
purchased by the Investor from the Company involves a high degree of risk.
The
Investor understands that no United States federal or state agency or any other
government or governmental agency has passed on or made any recommendation
or
endorsement of the securities being purchased by the Investor from the Company.
The Investor warrants that such Investor is able to bear the complete loss
of
such Investor’s investment in the securities being purchased by the Investor
from the Company.
5.9 Full
Disclosure.
No
representation or warranty made by the Investor in this Agreement and no
certificate or document furnished or to be furnished to the Company pursuant
to
this Agreement contains or will contain any untrue statement of a material
fact,
or omits or will omit to state a material fact necessary to make the statements
contained herein or therein not misleading. Except as set forth or referred
to
in this Agreement, Investor does not have any agreement or understanding with
any person relating to acquiring, holding, voting or disposing of any equity
securities of the Company.
5.10 Payment
of Due Diligence Expenses.
At
Closing the Escrow Agent shall disperse to the Investor Eighty-Five Thousand
Dollars ($85,000.00) for due diligence expenses.
ARTICLE
VI
COVENANTS
OF THE COMPANY
6.1 Registration
Rights.
The
Company shall cause the Registration Rights Agreement to remain in full force
and effect according to the provisions of the Registration Rights Agreement
and
the Company shall comply in all material respects with the terms
thereof.
6.2 Reservation
of Common Stock.
As of
the date hereof, the Company has reserved and the Company shall continue to
reserve and keep available at all times, free of preemptive rights, shares
of
Common Stock for the purpose of enabling the Company to issue the Shares
underlying the Preferred Stock and Warrants.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE13
OF
34
6.3 Compliance
with Laws.
The
Company hereby agrees to comply in all respects with the Company's reporting,
filing and other obligations under the Laws.
6.4 Filing
of Registration Statement on Form SB-2.
As
provided in the Registration Rights Agreement, on the day after the Closing
Date, the Company shall file with the SEC a Registration Statement on Form
SB-2
(the “SB-2”) covering the resale by the Investor of all Shares that may be
acquired by the Investor upon conversion of the Preferred Stock and exercise
of
the Warrants. The Company shall comply in all respects with its periodic
reporting and filing obligations under the 1934 Act. The Company will not take
any action or file any document (whether or not permitted by the 1934 Act or
the
rules thereunder) to terminate or suspend its reporting and filing obligations
under the 1934 Act until the Investor has disposed of all of its
Shares.
6.5 Corporate
Existence; Conflicting Agreements.
The
Company will take all steps necessary to preserve and continue the corporate
existence of the Company. The Company shall not enter into any agreement, the
terms of which agreement would restrict or impair the right or ability of the
Company to perform any of its obligations under this Agreement or any of the
other agreements attached as exhibits hereto.
6.6 OTC
Bulletin Board Qualification..
As soon
as practicable after the SB-2 is declared effective, the Company shall use
reasonable commercial efforts to have its Common Stock quoted on the OTC
Bulletin Board and to maintain such qualification.
6.7 Preferred
Stock.
On
or
prior to the Closing Date, the Company will cause to be cancelled all preferred
stock of the Company, if any. Without the prior written consent of the Investor,
such consent not to be unreasonably withheld, for a period of five yearsfrom
the
Closing Date, the Company will not issue any preferred stock of the Company,
except for the Preferred Stock issued to the Investor.
6.8 Convertible
Debt.
On
or
prior to the Closing Date, the Company will cause to be cancelled all
convertible debt in the Company. Without the prior written consent of the
Investor, such consent not to be unreasonably withheld, for a period of five
years from the closing the Company will not issue any convertible
debt.
6.9 Debt
Limitation.
Without
the prior written consent of the Investor, such consent not to be unreasonably
withheld, for five years after Closing the Company shall not to enter into
any
new borrowings of more than twice as much as the sum of the EBITDA from
recurring operations over the past four quarters.
6.10 Reset
Equity Deals.
On
or
prior to the Closing Date, the Company will cause to be cancelled any and all
reset features related to any shares outstanding that could result in additional
shares being issued. For a period of five years from the closing the Company
will not enter into any transactions that have any reset features that could
result in additional shares being issued.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE14
OF
34
6.11 Independent
Directors.
On or
before 30 days after the Closing Date, the Company shall have caused the
appointment of the majority of the board of directors to be qualified
independent directors, as defined in NASD Rule 4200(a)(15). If at any time
after
Closing the board shall not be composed in the majority of qualified independent
directors, the Company shall pay to the Investors, pro rata, as liquidated
damages and not as a penalty, an amount equal to twenty eight percent (22%)
of
the Purchase Price per annum, payable monthly in cash or Preferred Stock at
the
option of the Investor. The parties agree that the only damages payable for
a
violation of the terms of this Agreement with respect to which liquidated
damages are expressly provided shall be such liquidated damages. Nothing shall
preclude the Investor from pursuing or obtaining specific performance or other
equitable relief with respect to this Agreement. The parties hereto agree that
the liquidated damages provided for in this Section 6.11 constitute a reasonable
estimate of the damages that may be incurred by the Investor by reason of the
failure of the Company to appoint at least two independent directors in
accordance with the provision hereof.
6.12 Independent
Directors Become Majority of Audit and Compensation
Committees.
On or
before 30 days after the Closing Date, the Company will cause the appointment
of
a majority of independent directors to the audit and compensation committees
of
the board of directors of the Company. . If at any time after Closing such
independent directors do not compose the majority of the audit and compensation
committees, the Company shall pay to the Investors, pro rata, as liquidated
damages and not as a penalty, an amount equal to twenty eight percent (22%)
of
the Purchase Price per annum, payable monthly in cash or Preferred Stock at
the
option of the Investor. The parties agree that the only damages payable for
a
violation of the terms of this Agreement with respect to which liquidated
damages are expressly provided shall be such liquidated damages. Nothing shall
preclude the Investor from pursuing other remedies or obtaining specific
performance or other equitable relief with respect to this Agreement.
6.13 Use
of Proceeds.
The
Company will use the proceeds from the sale of the Preferred Stock and the
Warrants (excluding amounts paid by the Company for legal and administrative
fees in connection with the sale of such securities) for product rights, working
capital and acquisitions.
6.14 Preemptive
Right on Certain Issuances.
(a) Grant
of Rights.
Provided that this Agreement is consummated on or before September 6, 2006,
for
a period of two years after the Closing Date, the Company hereby grants to
the
Investor the right to purchase, pro rata, all (or any part) of any New
Securities (as defined in Section 6.14(i) below) that the Company may, from
time
to time during such period, propose to sell or issue. The Investor's pro rata
share of the New Securities (its “Pro Rata Amount”) for purposes of this Section
6.14, is equal to the ratio of (i) the number of shares of Common Stock then
issuable to the Investor assuming all of the Preferred Stock held by the
Investor is converted and all of the Warrants held by the Investor are exercised
in accordance with their respective terms (the “Investor’s Shares”) to (ii) the
sum of (A) the total number of shares of the Common Stock issued and outstanding
as of the date of such determination, plus (B) the total number of Investor
Shares .
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE15
OF
34
(b) Notice.
The
Company shall not issue, sell or exchange, agree to issue, sell or exchange,
or
reserve or set aside for issuance, sale or exchange any New Securities unless
the Company shall deliver to the Investor a written notice of any proposed
or
intended issuance, sale or exchange of New Securities (the "Preemptive Offer"),
which Preemptive Offer shall (i) identify and describe the New Securities,
(ii)
describe the price and other terms upon which they are to be issued, sold or
exchanged, and the number or amount of the New Securities to be issued, sold
or
exchanged, (iii) identify the persons or entities, if known, to which or with
which the New Securities are to be offered, issued, sold or exchanged and (iv)
offer to issue and sell to or exchange with such Investor such Investor's Pro
Rata Amount. The Investor shall have the right, for a period of 15 days
following delivery of the Preemptive Offer, to purchase or acquire, at a price
and upon the other terms specified in the Preemptive Offer, the number or amount
of New Securities described above. The Preemptive Offer by its terms shall
remain open and irrevocable for such 15-day period.
(c) Acceptance
of Preemptive Offer.
To
accept a Preemptive Offer, in whole or in part, a Investor must deliver a
written notice to the Company prior to the end of the 15-day Preemptive Offer
period, setting forth the portion of the Investor's Pro Rata Amount that such
Investor elects to purchase (the "Notice of Acceptance").
(d) Company
Sales of Refused Securities.
The
Company shall have 180 days from the expiration of the period set forth in
Section 6.14(c) above to issue, sell or exchange all or any part of such New
Securities as to which a Notice of Acceptance has not been given by the Investor
(the "Refused Securities"), but only upon terms and conditions that are not
materially more favorable to the purchaser of such New Securities as described
in the Preemptive Offer. Notwithstanding anything contained in this Section
6.14
to the contrary, the Preemptive Offer need not be given prior to the purchase
by
the party intending to purchase the New Securities described in the Preemptive
Offer; provided that (i) such Preemptive Offer is sent within five (5) days
after the sale to such party is consummated and remains open for a fifteen
(15)
day period from the receipt thereof, (ii) the Company has set aside a number
of
shares sufficient to satisfy the obligations of the Company pursuant to this
Section 6.14, and (iii) such New Securities purchased by the party intending
to
purchase the New Securities described in the Preemptive Offer are not considered
for purposes of determining each Investor's Pro Rata Amount pursuant to Section
6.14(a) hereof.
(e) Completion
of Purchase.
Upon the
closing of the issuance, sale or exchange of all or less than all the Refused
Securities, the Investor shall acquire from the Company, and the Company shall
issue to the Investor, the number or amount of New Securities specified in
the
Notices of Acceptance upon the terms and conditions specified in the Preemptive
Offer. The purchase by the Investor of any New Securities is subject in all
cases to the preparation, execution and delivery by the Company and the Investor
or like investors of a purchase agreement relating to such New Securities
reasonably satisfactory in form and substance to the Investor and the
Company.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE16
OF
34
“New
Securities” Defined.
“New
Securities” means (a) any shares of Common Stock, preferred stock or other
equity securities of the Company, whether now authorized or not issued after
the
date hereof; and (b) any options, warrants, convertible notes, or similar rights
issued after the date hereof that are or may become convertible into or
exercisable or exchangeable for, or that carry rights to subscribe for, any
equity securities of the Company (each, a “Derivative Security”); provided,
however, that the term “New Securities” does not include (i) securities issued
pursuant to the acquisition of another entity by the Company by merger,
consolidation, amalgamation, exchange of shares, the purchase of all or
substantially all of the assets, or otherwise; (ii) options issued to any
directors or employees of, or consultants to, the Company or its subsidiaries
pursuant to any incentive stock plan or other form of incentive compensation
approved by the Company’s Board of Directors (whether now authorized or not) and
all shares of Common Stock issued upon the exercise thereof; (iii) shares of
Common Stock issued upon the exercise of or conversion of any Derivative
Security that is outstanding on the date hereof; (iv) shares of Common Stock
or
other securities issued upon the exercise or conversion of any Derivative
Security as to which the Preemptive Offer has already been made or is otherwise
exempt from this Section; (v) shares of Common Stock or other capital stock
issued to the Company’s stockholders upon any stock split, stock dividend,
combination or other similar event with respect to the Company’s Common Stock or
other capital stock; and (vi) securities
of any type issued (a) to any broker, finder or agent acting on behalf of the
Company in satisfaction of commission payments (whether now due and owing or
not) or (b) for services rendered to the Company at any time (including, without
limitation, in connection with financing activities) and, to the extent that
any
such securities constitute Derivative Securities, the shares of Common Stock
that are issued upon the exercise or conversion thereof.
6.15 Price
Adjustment.
From
the
date hereof until the expiration of 48 months after the Closing Date or until
the Investor owns less than 5% of their Preferred Stock, whichever occurs first,
if the Company closes on the sale of a note or notes, shares of Common Stock,
or
shares of any class of Preferred Stock at a price per share of Common Stock,
or
with a conversion right to acquire Common Stock at a price per share of Common
Stock, that is less than the Conversion Value (as such term is defined in and
adjusted pursuant to the Certificate of Designations the Company shall make
a
post-Closing adjustment in the Conversion Value so that the Conversion Value
is
reduced to price per share of Common Stock or conversion price of the securities
sold.
6.16 Price
Adjustment Based on 2006 and 2007 Earnings Per Share.
| 6.16.1 |
In
the event the Company earns between $0.0306 and $0.0187 (40% Decline)
per
share (where such earnings in the paragraph shall always be defined
as
earnings on a pre tax fully diluted basis as reported in the audited
financial statements of the Company for the three months ended December
31, 2006 from continuing operations before any non-recurring items
(the
“2006 Audited Financials”)), the then current Conversion Value at the time
the 2006 Audited Financials are filed with the SEC shall be decreased
proportionally by 0% if the earnings are $0.0306 per share or greater
and
by 40% if the earnings are $0.0187 per share or less. For example,
if the
earnings are $0.0229 per share (25% decline) the then current Conversion
Value shall be reduced by 25%. Such adjustment shall be made within
five
(5) business days of the 2006 Audited Financials being filed with
the SEC,
and shall be cumulative upon any other changes to Conversion Value
that
may already have been made.
|
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE 17
OF
34
| 6.16.2 |
In
the event the Company earns between $0.19 and $0.1446 (25% Decline)
per
share (where such earnings in the paragraph shall always be defined
as
earnings on a pre tax fully diluted basis as reported in the audited
financial statements of the Company for the fiscal year ended December
31,
2007 from continuing operations before any non-recurring items (the
“2007
Audited Financials”)) the then current Conversion Value at the time the
2007 Audited Financials are filed with the SEC shall be decreased
proportionally by 0% if the earnings are $0.19 per share or greater
and by
25% if the earnings are $0.1446 per share or less. For example, if
the
earnings are $0.163 per share (15% decline) the then current Conversion
Value shall be reduced by 15%. Such adjustment shall be made within
five
(5) business days of the 2007 Audited Financials being filed with
the SEC,
and shall be cumulative upon any other changes to Conversion Value
to that
may already have been made.
|
| 6.16.3 |
For
purpose of determining EBITDA Per Share on a fully-diluted basis,
all
shares of Common Stock issuable upon conversion of convertible securities
and upon exercise of warrants and options shall be deemed to be
outstanding, regardless of whether (i) such shares are treated as
outstanding for determining diluted earnings per share under GAAP,
(ii)
such securities are “in the money,” or (iii) such shares may be issued as
a result of the 4.9% Limitation. The per share amounts set forth
in
Sections 6.16.1 and 6.16.2 of this Agreement shall be adjusted in
accordance with GAAP to reflect any stock dividend, split, distribution,
reverse split or combination of shares or other
recapitalization.
|
6.17 Insider
Selling.
The
earliest any “Insiders” can start selling their shares shall be one year from
the date the registration statement is declared effective. Insiders shall
include all officers and directors of the Company. ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ and
the
Investor shall not be considered “Insiders”.
6.18 Employment
and Consulting Contracts.
For
five
years after the Closing Company must have a unanimous opinion from the
Compensation Committee of the Board of Directors that any awards other than
salary are usual, appropriate and reasonable for any officer, director,
employee or consultant holding a similar position in other fully reporting
public companies with independent majority boards with similar market
capitalizations in the same industry with securities listed on the OTCBB, ASE,
NYSE or NASDAQ.
6.19 Subsequent
Equity Sales.
From
the
date hereof until such time as no Purchaser holds any of the Securities, the
Company shall be prohibited from effecting or entering into an agreement to
effect any Subsequent Financing involving a “Variable
Rate Transaction”
or
an
“MFN
Transaction”
(each
as defined below). The term “Variable
Rate Transaction”
shall
mean a transaction in which the Company issues or sells (i) any debt or equity
securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at
a
conversion, exercise or exchange rate or other price that is based upon and/or
varies with the trading prices of or quotations for the shares of Common Stock
at any time after the initial issuance of such debt or equity securities, or
(B)
with a conversion, exercise or exchange price that is subject to being reset
at
some future date after the initial issuance of such debt or equity security
or
upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock.
The
term “MFN
Transaction”
shall
mean a transaction in which the Company issues or sells any securities in a
capital raising transaction or series of related transactions which grants
to an
investor the right to receive additional shares based upon future transactions
of the Company on terms more favorable than those granted to such investor
in
such offering. Any Purchaser shall be entitled to obtain injunctive relief
against the Company to preclude any such issuance, which remedy shall be in
addition to any right to collect damages. Notwithstanding the foregoing, this
Section 6.17 shall not apply in respect of an Exempt Issuance, except that
no
Variable Rate Transaction or MFN Transaction shall be an Exempt
Issuance.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE18
OF
34
6.20 Stock
Splits.
All
forward and reverse stock splits shall effect all equity and derivative holders
proportionately.
ARTICLE
VII
COVENANTS
OF THE INVESTOR
7.1 Compliance
with Law.
The
Investor's trading activities with respect to shares of the Company's Common
Stock will be in compliance with all applicable state and federal securities
laws, rules and regulations and rules and regulations of any public market
on
which the Company's Common Stock is listed.
7.2 Transfer
Restrictions. The
Investor acknowledges that (1) the Preferred Stock, Warrants and shares
underlying the Preferred Stock and Warrants have not been registered under
the
provisions of the 1933 Act, and may not be transferred unless (A) subsequently
registered thereunder or (B) the Investor shall have delivered to the Company
an
opinion of counsel, reasonably satisfactory in form, scope and substance to
the
Company, to the effect that the Preferred Stock, Warrants and shares underlying
the Notes and Warrants to be sold or transferred may be sold or transferred
pursuant to an exemption from such registration; and (2) any sale of the
Preferred Stock, Warrants and shares underlying the Preferred Stock and Warrants
made in reliance on Rule 144 promulgated under the 1933 Act may be made only
in
accordance with the terms of said Rule and further, if said Rule is not
applicable, any resale of such securities under circumstances in which the
seller, or the person through whom the sale is made, may be deemed to be an
underwriter, as that term is used in the 1933 Act, may require compliance with
some other exemption under the 1933 Act or the rules and regulations of the
SEC
thereunder.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE19
OF
34
7.3 Restrictive
Legend. The
Investor acknowledges and agrees that the Preferred Stock, the Warrants and
the
Shares underlying the Preferred Stock and Warrants, and, until such time as
the
Shares underlying the Preferred Stock and Warrants have been registered under
the 1933 Act and sold in accordance with an effective Registration Statement,
certificates and other instruments representing any of the Shares, shall bear
a
restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of any such securities):
"THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE
SECURITIES LAWS AND NEITHER SUCH SHARES NOR ANY INTEREST THEREIN MAY BE OFFERED,
SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION
STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY
APPLICABLE STATE SECURITIES LAWS, OR (2) IN ACCORDANCE WITH THE PROVISIONS
OF
REGULATION S, OR (3) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT."
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE20
OF
34
ARTICLE
VIII
CONDITIONS
PRECEDENT TO THE COMPANY’S OBLIGATIONS
The
obligation of the Company to consummate the transactions contemplated hereby
shall be subject to the fulfillment, on or prior to Closing Date, of the
following conditions:
8.1 No
Termination.
This
Agreement shall not have been terminated pursuant to Article X
hereof.
8.2 Representations
True and Correct.
The
representations and warranties of the Investor contained in this Agreement
shall
be true and correct in all material respects on and as of the Closing Date
with
the same force and effect as if made on as of the Closing Date.
8.3 Compliance
with Covenants.
The
Investor shall have performed and complied in all material respects with all
covenants, agreements, and conditions required by this Agreement to be performed
or complied by it prior to or at the Closing Date.
8.4 No
Adverse Proceedings.
On the
Closing Date, no action or proceeding shall be pending by any public authority
or individual or entity before any court or administrative body to restrain,
enjoin, or otherwise prevent the consummation of this Agreement or the
transactions contemplated hereby or to recover any damages or obtain other
relief as a result of the transactions proposed hereby.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE21
OF
34
ARTICLE
IX
CONDITIONS
PRECEDENT TO INVESTOR’S OBLIGATIONS
The
obligation of the Investors to consummate the transactions contemplated hereby
shall be subject to the fulfillment, on or prior to Closing Date unless
specified otherwise, of the following conditions:
9.1 No
Termination.
This
Agreement shall not have been terminated pursuant to Article X
hereof.
9.2 Representations
True and Correct.
The
representations and warranties of the Company contained in this Agreement shall
be true and correct in all material respects on and as of the Closing Date
with
the same force and effect as if made on as of the Closing Date.
9.3 Compliance
with Covenants .
The
Company shall have performed and complied in all material respects with all
covenants, agreements, and conditions required by this Agreement to be performed
or complied by it prior to or at the Closing Date.
9.4 No
Adverse Proceedings.
On the
Closing Date, no action or proceeding shall be pending by any public authority
or individual or entity before any court or administrative body to restrain,
enjoin, or otherwise prevent the consummation of this Agreement or the
transactions contemplated hereby or to recover any damages or obtain other
relief as a result of the transactions proposed hereby.
ARTICLE
X
TERMINATION,
AMENDMENT AND WAIVER
10.1 Termination.
This
Agreement may be terminated at any time prior to the Closing Date
10.1.1 by
mutual
written consent of the Investor and the Company;
10.1.2 by
the
Company upon a material breach of any representation, warranty, covenant or
agreement on the part of the Investor set forth in this Agreement, or the
Investor upon a material breach of any representation, warranty, covenant or
agreement on the part of the Company set forth in this Agreement, or if any
representation or warranty of the Company or the Investor, respectively, shall
have become untrue, in either case such that any of the conditions set forth
in
Article VIII or Article IX hereof would not be satisfied (a "Terminating
Breach"),
and
such breach shall, if capable of cure, not have been cured within five (5)
business days after receipt by the party in breach of a notice from the
non-breaching party setting forth in detail the nature of such
breach.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE22
OF
34
10.2 Effect
of Termination.
Except
as otherwise provided herein, in the event of the termination of this Agreement
pursuant to Section 10.1 hereof, there shall be no liability on the part of
the
Company or the Investor or any of their respective officers, directors, agents
or other representatives and all rights and obligations of any party hereto
shall cease; provided that in the event of a Terminating Breach, the breaching
party shall be liable to the non-breaching party for all costs and expenses
incurred by the non-breaching party not to exceed $50,000.00.
10.3 Amendment.
This
Agreement may be amended by the parties hereto any time prior to the Closing
Date by an instrument in writing signed by the parties hereto.
10.4 Waiver.
At any
time prior to the Closing Date, the Company or the Investor, as appropriate,
may: (a) extend the time for the performance of any of the obligations or other
acts of other party or; (b) waive any inaccuracies in the representations and
warranties contained herein or in any document delivered pursuant hereto which
have been made to it or them; or (c) waive compliance with any of the agreements
or conditions contained herein for its or their benefit. Any such extension
or
waiver shall be valid only if set forth in an instrument in writing signed
by
the party or parties to be bound hereby.
ARTICLE
XI
GENERAL
PROVISIONS
11.1 Transaction
Costs.
Except
as otherwise provided herein, each of the parties shall pay all of his or its
costs and expenses (including attorney fees and other legal costs and expenses
and accountants’ fees and other accounting costs and expenses) incurred by that
party in connection with this Agreement; provided, the Company shall pay
Investor such due diligence expenses as described in section 5.10.
11.2 Indemnification.
The
Investor agrees to indemnify, defend and hold the Company (following the Closing
Date) and its officers and directors harmless against and in respect of any
and
all claims, demands, losses, costs, expenses, obligations, liabilities or
damages, including interest, penalties and reasonable attorney’s fees, that it
shall incur or suffer, which arise out of or result from any breach of this
Agreement by such Investor or failure by such Investor to perform with respect
to any of its representations, warranties or covenants contained in this
Agreement or in any exhibit or other instrument furnished or to be furnished
under this Agreement. The Company agrees to indemnify, defend and hold the
Investor harmless against and in respect of any and all claims, demands, losses,
costs, expenses, obligations, liabilities or damages, including interest,
penalties and reasonable attorney’s fees, that it shall incur or suffer, which
arise out of, result from or relate to any breach of this Agreement or failure
by the Company to perform with respect to any of its representations, warranties
or covenants contained in this Agreement or in any exhibit or other instrument
furnished or to be furnished under this Agreement. In no event shall the Company
or the Investors be entitled to recover consequential or punitive damages
resulting from a breach or violation of this Agreement nor shall any party
have
any liability hereunder in the event of gross negligence or willful misconduct
of the indemnified party. In the event of a breach of this Agreement by the
Company, the Investor shall be entitled to pursue a remedy of specific
performance upon tender into the Court an amount equal to the Purchase Price
hereunder. The indemnification by the Investor shall be limited to
$50,000.00.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE23
OF
34
11.3 Headings.
The
table of contents and headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation
of
this Agreement.
11.4 Entire
Agreement.
This
Agreement (together with the Schedule, Exhibits, Warrants and documents referred
to herein) constitute the entire agreement of the parties and supersede all
prior agreements and undertakings, both written and oral, between the parties,
or any of them, with respect to the subject matter hereof.
11.5 Notices.
All
notices and other communications hereunder shall be in writing and shall be
deemed to have been given (i) on the date they are delivered if delivered in
person; (ii) on the date initially received if delivered by facsimile
transmission followed by registered or certified mail confirmation; (iii) on
the
date delivered by an overnight courier service; or (iv) on the third business
day after it is mailed by registered or certified mail, return receipt requested
with postage and other fees prepaid as follows:
If
to the
Company:
▇▇▇
▇▇▇▇▇
▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention:
President
With
a
copy to:
Guzov
Ofsink, LLC
▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇
▇▇▇▇,
▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Facsimile
No.: 212-688-7273
Attn:
▇▇▇▇▇▇ ▇▇▇▇▇▇, Esq.
If
to
the Investor:
▇▇▇▇▇▇
Partners L.P.
c/o
Barron Capital Advisors, LLC
▇▇▇
▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇
▇▇▇▇▇
▇▇▇
▇▇▇▇,
▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attn:
▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE24
OF
34
11.6 Severability.
If any
term or other provision of this Agreement is invalid, illegal or incapable
of
being enforced by any rule of law or public policy, all other conditions and
provisions of this Agreement shall nevertheless remain in full force and effect
so long as the economic or legal substance of the transactions contemplated
hereby is not affected in any manner materially adverse to any party. Upon
such
determination that any such term or other provision is invalid, illegal or
incapable of being enforced, the parties hereto shall negotiate in good faith
to
modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner to the end that the transactions
contemplated hereby are fulfilled to the extent possible.
11.7 Binding
Effect.
All the
terms and provisions of this Agreement whether so expressed or not, shall be
binding upon, inure to the benefit of, and be enforceable by the parties and
their respective administrators, executors, legal representatives, heirs,
successors and assignees.
11.8 Preparation
of Agreement.
This
Agreement shall not be construed more strongly against any party regardless
of
who is responsible for its preparation. The parties acknowledge each contributed
and is equally responsible for its preparation.
11.9 Governing
Law.
This
Agreement shall be governed by, and construed in accordance with, the laws
of
the State of New York, without giving effect to applicable principles of
conflicts of law.
11.10
Jurisdiction.
This
Agreement shall be exclusively governed by and construed in accordance with
the
laws of the State of New York. If any action is brought among the parties with
respect to this Agreement or otherwise, by way of a claim or counterclaim,
the
parties agree that in any such action, and on all issues, the parties
irrevocably waive their right to a trial by jury. Exclusive jurisdiction and
venue for any such action shall be the Federal Courts serving the State of
New
York. In the event suit or action is brought by any party under this Agreement
to enforce any of its terms, or in any appeal therefrom, it is agreed that
the
prevailing party shall be entitled to reasonable attorneys fees to be fixed
by
the arbitrator, trial court, and/or appellate court.
11.11
Preparation
and Filing of SEC filings.
The
Investor shall reasonably assist and cooperate with the Company in the
preparation of all filings with the SEC after the Closing Date due after the
Closing Date.
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE25
OF
34
11.12 Further
Assurances, Cooperation.
Each
party shall, upon reasonable request by the other party, execute and deliver
any
additional documents necessary or desirable to complete the transactions herein
pursuant to and in the manner contemplated by this Agreement. The parties hereto
agree to cooperate and use their respective best efforts to consummate the
transactions contemplated by this Agreement.
11.13 Survival.
The
representations, warranties, covenants and agreements made herein shall survive
the Closing of the transaction contemplated hereby.
11.14 Third
Parties.
Except
as disclosed in this Agreement, nothing in this Agreement, whether express
or
implied, is intended to confer any rights or remedies under or by reason of
this
Agreement on any persons other than the parties hereto and their respective
administrators, executors, legal representatives, heirs, successors and
assignees. Nothing in this Agreement is intended to relieve or discharge the
obligation or liability of any third persons to any party to this Agreement,
nor
shall any provision give any third persons any right of subrogation or action
over or against any party to this Agreement.
11.15 Failure
or Indulgence Not Waiver; Remedies Cumulative.
No
failure or delay on the part of any party hereto in the exercise of any right
hereunder shall impair such right or be construed to be a waiver of, or
acquiescence in, any breach of any representation, warranty, covenant or
agreement herein, nor shall nay single or partial exercise of any such right
preclude other or further exercise thereof or of any other right. All rights
and
remedies existing under this Agreement are cumulative to, and not exclusive
of,
any rights or remedies otherwise available.
11.16 Counterparts.
This
Agreement may be executed in one or more counterparts, and by the different
parties hereto in separate counterparts, each of which when executed shall
be
deemed to be an original, but all of which taken together shall constitute
one
and the same agreement. A facsimile transmission of this signed Agreement shall
be legal and binding on all parties hereto.
[SIGNATURES
ON FOLLOWING PAGE]
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE26
OF
34
IN
WITNESS WHEREOF,
the
Investors and the Company have as of the date first written above executed
this
Agreement.
| THE COMPANY: | ||||
| LAB123, INC. | ||||
|
By:
Title: |
/s/ ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇
|
|||
| INVESTOR: | |||
|
▇▇▇▇▇▇
PARTNERS LP
By:
▇▇▇▇▇▇ Capital Advisors, LLC, its General Partners
|
|||
| /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ | |||
|
|
|||
| ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ President
▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇
▇▇▇▇ ▇▇ ▇▇▇▇▇
|
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE27
OF
34
Schedule
A
|
NAME
AND ADDRESS
|
AMOUNT
OF
INVESTMENT |
NUMBER
OF SHARES
OF
COMMON STOCK
INTO
WHICH PREFERRED
STOCK
IS CONVERTIBLE
|
NUMBER
OF SHARES
UNDERLYING WARRANTS |
|
▇▇▇▇▇▇
Partners LP
▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇
▇▇▇▇▇
▇▇▇
▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attn:
▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
|
$2,000,000.00
|
3,774,000
|
A:
1,887,000
B: 1,887,000 Total: 3,774,000 |
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE28
OF
34
Schedule
4.3.2 - Capitalization
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE29
OF
34
Schedule
4.8 - List of Brokers
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE30
OF
34
Exhibit
A
Form
of Certificate of Deisgnation of Preferences, Rights and
Limitations
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE31
OF
34
Exhibit B
Registration
Rights Agreement
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE32
OF
34
Exhibit
C
Warrants
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE33
OF
34
Exhibit
D
Escrow
Agreement
PREFERRED
STOCK PURCHASE AGREEMENT BETWEEN
LAB123
CORPORATION AND ▇▇▇▇▇▇ PARTNERS LP
PAGE34
OF
34